CLARITHROMYCIN Oral Suspension 250/5 MG/5ml
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
26-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CLARITHROMYCIN
Available from:
Ranbaxy Ireland Limited
Dosage:
250/5 MG/5ml
Pharmaceutical form:
Oral Suspension
Authorization date:
2006-06-02
Summary of Product characteristics
IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. NO.540 OF 2007)
PA0408/063/004
Case No: 2043628
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
RANBAXY IRELAND LIMITED
SPAFIELD, CORK ROAD, CASHEL, CO. TIPPERARY, IRELAND
an authorisation, subject to the provisions of the said Regulations, in respect of the product
CLARITHROMYCIN 250MG/5ML ORAL SUSPENSION
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 13/12/2007 until 31/05/2011.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 04/01/2008_
_CRN 2043628_
_page number: 1_
PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Clarithromycin 250 mg/5ml Oral Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5 ml of the suspension contains clarithromycin 250 mg.
1 ml of the suspension contains clarithromycin 50 mg.
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Granules for oral suspension.
White to off-white granules forming white to off-white suspension on reconstitution with water.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Treatment of the following infections in children when caused by clarithromycin-susceptible organisms:
- Lower respiratory tract infections such as community acquir
Read the complete document
